Table of Contents

company-logo

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Biohaven Pharmaceutical Dividend Announcement

• Biohaven Pharmaceutical does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Biohaven Pharmaceutical dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Biohaven Pharmaceutical Dividend History

Biohaven Pharmaceutical Dividend Yield

Biohaven Pharmaceutical current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Biohaven Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:

Biohaven Pharmaceutical Financial Ratios

P/E ratio-5.07
PEG ratio-0.24
P/B ratio12.92
ROE-225.12%
Payout ratio0.00%
Current ratio2.89
Quick ratio2.89
Cash Ratio0.55

Biohaven Pharmaceutical Dividend FAQ

Does Biohaven Pharmaceutical stock pay dividends?
Biohaven Pharmaceutical does not currently pay dividends to its shareholders.
Has Biohaven Pharmaceutical ever paid a dividend?
No, Biohaven Pharmaceutical has no a history of paying dividends to its shareholders. Biohaven Pharmaceutical is not known for its dividend payments.
Why doesn't Biohaven Pharmaceutical pay dividends?
There are several potential reasons why Biohaven Pharmaceutical would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Biohaven Pharmaceutical ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Biohaven Pharmaceutical has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Biohaven Pharmaceutical a dividend aristocrat?
Biohaven Pharmaceutical is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Biohaven Pharmaceutical a dividend king?
Biohaven Pharmaceutical is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Biohaven Pharmaceutical a dividend stock?
No, Biohaven Pharmaceutical is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Biohaven Pharmaceutical stocks?
To buy Biohaven Pharmaceutical you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Biohaven Pharmaceutical stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.